Helius Medical Technologies Disputes PoNS Device Reimbursement Rates
Helius Medical Technologies, Inc. (NASDAQ: HSDT), based in Newtown, has recently raised concerns regarding the reimbursement rates set by the Centers for Medicare & Medicaid Services (CMS) for its innovative PoNS Mouthpiece. The reimbursement for the device, identified by HCPCS code A4594, has been placed at $2,963.30, with this rate commencing from a future date. Meanwhile, the CMS has decided to defer the reimbursement decision for the PoNS Controller to a later cycle.
Significance of the PoNS Device
Helius’s mission revolves around addressing balance and gait issues through neuromodulation therapies. The company believes that the current reimbursement rate does not reflect the extensive research and development investments that qualified the PoNS device for Breakthrough Device status from the FDA. They plan to support this claim by providing further evidence to CMS arguing that the price should adequately represent its value, especially for patients grappling with conditions like multiple sclerosis (MS).
Leadership's Vision
Dane Andreeff, the President and CEO of Helius, remains optimistic about obtaining a more favorable reimbursement policy for both the PoNS Mouthpiece and Controller. A better reimbursement structure could enhance access for patients while bolstering the company's financial performance and revenue. Helius is also pursuing authorization to expand the device's use in treating strokes, which further emphasizes their commitment to improving patient outcomes.
CMS's Current Position and Helius's Challenges
The CMS has classified the PoNS Mouthpiece as a critical accessory, applicable for lump-sum payment. However, Helius strongly believes that the historical temporary pricing should not dictate the current reimbursement rate. They advocate for a payment structure aligned more closely with negotiated rates across various government and private entities, including the Veterans Affairs (VA) and Department of Defense (DoD).
Future Evaluations and Potential Appeals
As CMS defers the reimbursement evaluation for the PoNS Controller, they have preliminarily likened it to a transcutaneous electrical nerve stimulation (TENS) device. Helius is preparing to contest this comparison in an upcoming public meeting, and hopes to provide a clearer perspective on the device's unique benefits.
Innovation in Neuromodulation Therapy
Recognized for the Portable Neuromodulation Stimulator (PoNS), Helius offers a non-invasive therapy tailored for patients with specific neurological conditions. Currently, the device has secured authorization for sale not just in the United States but also in Canada and Australia for various medical guidelines.
Recent Studies and Financial Outlook
In recent developments, Helius has generated buzz with the initial results from the PoNSTEP study. This crucial study focuses on the PoNS Therapy’s effectiveness in improving gait among MS patients. Early findings illustrate a notable improvement in Dynamic Gait Index (DGI) scores, along with a significant correlation between adherence to therapy and increases in DGI scores, particularly in the second phase of the study that was conducted at home.
Financial Status and Strategic Initiatives
While Helius has revealed a decline in revenue during the second quarter of 2024, the company has secured financial stability projected into 2025 following a successful public offering. Moreover, it is preparing for a submission to the FDA for the authorization of stroke therapy and is searching for opportunities to expand PoNS's use to traumatic brain injuries.
Expanding Accessibility and Future Preparations
Despite experiencing financial hurdles, Helius has strategically focused on enhancing the accessibility of PoNS therapy while establishing partnerships with federal bodies such as Lovell Government Services. An impending Medicare reimbursement expected from a future date could bolster the company's revenue, pointing toward the potential for Helius to solidify and expand its presence in the healthcare space.
Frequently Asked Questions
What is the PoNS device?
The PoNS device is a Portable Neuromodulation Stimulator that is aimed at improving balance and gait in patients with neurological disorders.
Why is Helius Medical Technologies contesting CMS reimbursement rates?
Helius argues that the reimbursement rates set by CMS do not align with the significant research investments made for the PoNS device.
What are the next steps for Helius regarding CMS?
Helius plans to present additional evidence to CMS and is preparing to challenge the preliminary classification of the PoNS Controller.
Is Helius expanding its therapy offerings?
Yes, Helius is pursuing FDA authorization for the use of the PoNS device in stroke treatments and investigating its application for traumatic brain injury patients.
What financial steps has Helius taken recently?
Helius secured a successful public offering which has extended its financial stability into the upcoming years despite experiencing recent revenue declines.
